New strategies for enhancing the immunogenicity of tumors

Current Opinion in Immunology

Volumn 5, Issue 5, 1993, Pages 719-725

  Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RECOMBINANT VACCINE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; GENETIC MANIPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMAL; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CYTOKINES; GENE THERAPY; HUMAN; IMMUNOTHERAPY, ACTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; T-LYMPHOCYTES; VACCINES;

EID: 0027501323     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/0952-7915(93)90127-E     Document Type: Article

References (33)

1. Cell Biology of Antigen Processing and Presentation to MHC Class I Molecule-Restricted T Cells
2. T Cell Recognition of Transforming Proteins Encoded By Mutated ras Proto-Oncogenes
3. Human T Lymphocytes Recognize a Peptide of Single Point-Mutated, Oncogenic Ras Proteins
4. Structure for the Gene Coding for Tum Antigen P91A: A Peptide Encoded By the Mutated Exon is Recognized with Ld by Cytolytic T Cells
5. A Gene Encoding an Antigen Recognized Cytotoxic T Lymphocytes on a Human Melanoma
6. The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas
7. Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2- Restricted Cytotoxic T Cell Clones From Melanoma Patients
8. Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-γ
9. b Molecule
10. Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes is Mediated by at Least Six Shared Peptide Epitopes
11. Abrogation of Metastatic Properties of Tumor Cells by de novo Expression of H2K Antigens Following H-2 Gene Transfection
12. Selective Rejection of H-2 Deficient Lymphoma Variants Suggests Alternative Immune Defense Strategy
13. d)
14. Immunotherapy of Malignancy by in Vivo Gene Transfer Into Tumors
15. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
16. Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation
17. CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones
18. Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
19. Regulation of Interleukin-2 Gene Enhancer Activity By the T Cell Accessory Molecule CD28
20. Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig
21. + T Cells by B7-Transfected Melanoma Cells
22. Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4
23. Local Cytokine Availability Elicits Tumor Rejection and Systemic Immunity Through Granulocyte-T-Lymphocyte Cross-Talk
24. Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response
25. Interleukin-2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity
26. Murine Interleukin-4 Displays Potent Anti-Tumor Activity in Vivo
27. Murine Tumor Cells Transduced With the Gene for Tumor Necrosis Factor-α
28. + T Cell-Dependent Tumor Rejection
29. Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence Against Parental Metastatic Cells
30. Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine GM-CSF Stimulates Potent, Specific and Long Lasting Anti-Tumor Immunity
31. Vaccinia Virus: A Selectable Eukaryotic Cloning and Expression Vector
32. Induction of Immune Responses in Patients With B Cell Lymphoma Against the Surface Immunoglobulin Idio type Expressed by Their Tumors
33. A Novel Vaccine for B Cell Lymphoma: Idiotype/Granulocyte-Macrophage Colony Stimulating Factor Fusion Protein